Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms (Q38106623)

29 August 2017

title

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms (English)

1 reference

29 August 2017

Neha Bhagwat

1 reference

29 August 2017

Ross L Levine

series ordinal

1 reference

29 August 2017

Priya Koppikar

series ordinal

1 reference

29 August 2017

publication date

14 May 2013

1 reference

International Journal of Hematology

29 August 2017

published in

1 reference

29 August 2017

1 reference

29 August 2017

1 reference

29 August 2017

page(s)

695-702

1 reference

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

The role of mutations in epigenetic regulators in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

The Janus kinase family and signaling through members of the cytokine receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

JAK2 inhibitors: A reality? A hope?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Intrinsic resistance to JAK2 inhibition in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1353-5

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

21 January 2018

1 reference

12 December 2020

Some speculations on the myeloproliferative syndromes.

1 reference

12 December 2020

JAK protein tyrosine kinases: their role in cytokine signalling

1 reference

12 December 2020

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

12 December 2020

JAK2, a third member of the JAK family of protein tyrosine kinases

1 reference

12 December 2020

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

1 reference

12 December 2020

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis

1 reference

12 December 2020

10.1007/S12185-013-1353-5

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1052190754

0 references

1 reference